Purpose: Our aim was to analyse the clinical effect of intravitreal bevacizumab treatment
for macular oedema due to central/branch retinal vein occlusion (CRVO/BRVO). The end
points were final best-corrected visual acuity (BCVA), BCVA improvement, final central
1-mm macular subfield thickness (CST) and change in CST. Methods: Our study included
34 CRVO and 25 BRVO patients. Patients received intravitreal bevacizumab (IVB) treatment
at our department. Our control group consisted of 50 CRVO and 30 BRVO patients, who
had not received this treatment because their disease developed before the anti-VEGF
treatment became available. For statistical analysis, two-samplet-test, Pearson's
correlation, and ANOVA were used. The level of significance was defined atp < 0.05.
Results: With the two-sample t-test we found significant improvement of BCVA in the
IVB-treated group (CRVO: 0.171 +/- 0.270, p1 = 3.25x10-4; BRVO: 0.215 +/- 0.282, p2
= 5.52x10-4). The difference in BCVA improvement was also significant compared to
the control group (CRVO: p1 = 3.46x10-4; BRVO: p2 = 0.003). Significant decrease was
observed in the CST in the treated group (CRVO: -345.114 +/- 280.577, p1 = 6.94x10-9;
BRVO: -151.875 +/- 174.341, p2 = 1.67x10-4). In case of BRVO patients the final BCVA
was significantly better in the treated group (0.617 +/- 0.334) compared to the control
group (0.406 +/- 0.357),p = 0.016. Conclusion: IVB treatment results in significantly
better final visual acuity and leads to significantly increased BCVA improvement compared
to patients with RVO-induced macular oedema receiving no treatment.
